S&P 500
7,615.40
-0.09%
Dow Jones
51,327.00
-0.09%
Nasdaq 100
30,644.80
-0.23%
Russell 2000
2,928.08
-0.17%
FTSE 100
10,381.30
-0.06%
Nikkei 225
68,144.20
+0.95%

Investing

Generex Biotechnology (GNBT): Nice Wild Speculation

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published

Generex Biotechnology (GNBT) describes itself as "the leader in drug delivery for metabolic diseases through the inner lining of the mouth". Not a leader, the leader. Today, a small investment bank outfit called Rodman and Renshaw opened coverage on the company with a "market outperform" rating.

The investment house said: "Our analysis indicates that Generex’s oral insulin, Oral-lyn, could be a significant player in the non-injectable insulin market. We believe that Oral-lyn’s product profile, combined with strong clinical data and expected rapid growth in the global diabetic population, could result in > $600 MM in revenues by 2013."

That’s right,"could result" in 2013. The stock moved up 42% to $1.79.

For the present, the company had $45,000 in revenue in the last reported quarter. The company’s operating loss for that period was $5.5 million.

Talk about a risky investment.

Douglas A. McIntyre

Follow 24/7 Wall St. on Google
Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Douglas A. McIntyre |

Biotech Busine$$ Daily (ALKS, CADX, CVTX, MNKD, GNBT, PPHM)

Alkermes (NASDAQ: ALKS) and Johnson & Johnson Pharmaceutical Research and Developed today submitted paperwork seeking approval of their partnership drug,…

Trey Thoelcke |

3 Sleeper Biotechs That Could Bounce Back Strong in 2017

2016 was hard for biotech stocks, some more than others. These three present a buy low opportunity.

Lee Jackson |

3 Medical Device Stocks to Buy as Obesity and Diabetes Epidemic Spreads

Cowen analysts point out that an estimated 300 million people have diabetes globally, and that number is expected to skyrocket…

Sanofi Just Can’t Catch a Break, Knocking at Major Support Again
Trey Thoelcke |

Sanofi Just Can’t Catch a Break, Knocking at Major Support Again

At this point, bad news is coming in consistently to the point that any significant piece of good news could…

Douglas A. McIntyre |

The Five Growth Biotech Names To Watch Right Now

Alnylam (Nasdaq: ALNY) leads a short list of some of the fastest-growing biotech stocks where analyst estimate revisions continue to…

Did Eli Lilly Just Find the Holy Grail of Weight Loss?
Rich Duprey |

Did Eli Lilly Just Find the Holy Grail of Weight Loss?

Eli Lilly (NYSE:LLY | LLY Price Prediction) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss.…

Visa, Eli Lilly or Netflix— Which Stock Will Be A Trillion Dollar Company Next?
Vandita Jadeja |

Visa, Eli Lilly or Netflix— Which Stock Will Be A Trillion Dollar Company Next?

Companies are always in the race for the top spot, and the only way to achieve it is by reaching…

3 GLP-1 Stocks to Buy Now For Big Long-Term Gains
Chris MacDonald |

3 GLP-1 Stocks to Buy Now For Big Long-Term Gains

The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive. Indeed, the growth various…

3 Biotechs That Just Announced Successful Phase 2 Trials
Trey Thoelcke |

3 Biotechs That Just Announced Successful Phase 2 Trials

Here are three biotechs that just recently announced successful Phase 2 trial data for drugs with very big addressable markets.

Top Gaining Stocks

Hewlett Packard Enterprise
HPE • Vol: 153,197,465
Enphase Energy
ENPH • Vol: 8,360,053
Corning
GLW • Vol: 18,152,646
Alexandria Real Estate Equities
ARE • Vol: 4,337,015
Aptiv
APTV • Vol: 6,761,325

Top Losing Stocks

Trade Desk
TTD • Vol: 21,905,513
Intuit
INTU • Vol: 7,383,018
Coterra Energy
CTRA • Vol: 73,319,495
Cboe Global Markets
CBOE • Vol: 5,000,011
HP
HPQ • Vol: 29,259,826